Wedbush Upgrades Zentalis Pharma to Neutral, Announces $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has upgraded Zentalis Pharma (NASDAQ:ZNTL) from Underperform to Neutral and set a price target of $4.
August 12, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has upgraded Zentalis Pharma from Underperform to Neutral and set a price target of $4.
The upgrade from Underperform to Neutral by a reputable analyst and the announcement of a $4 price target is likely to have a positive short-term impact on Zentalis Pharma's stock price as it reflects improved sentiment and potential for price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100